Neuroinflammation of the central and peripheral nervous system: an update

被引:17
作者
Stueve, O. [1 ,2 ,3 ]
Zettl, U. [4 ]
机构
[1] Dallas VA Med Ctr, VA North Texas Hlth Care Syst, Neurol Sect, Dallas, TX USA
[2] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA
[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-80290 Munich, Germany
[4] Univ Rostock, Dept Neurol, D-18055 Rostock, Germany
关键词
autoimmunity; inflammation; neuroimmunology;
D O I
10.1111/cei.12260
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Inflammatory disorders of the peripheral nervous system (PNS) and central nervous system (CNS) are common, and contribute substantially to physical and emotional disability of affected individuals. Often, the afflicted are young and in their active years. In the past, physicians and scientists often had very little to offer in terms of diagnostic precision and therapeutic effectiveness. During the past two decades, both of these relative shortcomings have clearly improved. Some of the recent developments in clinical neuroimmunology are illustrated in this special edition of Clinical and Experimental Immunology.
引用
收藏
页码:333 / 335
页数:3
相关论文
共 9 条
  • [1] Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls
    Berlit, P.
    Kraemer, M.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 419 - 424
  • [2] Diagnosis, pathogenesis and treatment of myositis: recent advances
    Carstens, P. -O.
    Schmidt, J.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 349 - 358
  • [3] CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders
    Dudesek, A.
    Rimmele, F.
    Tesar, S.
    Kolbaske, S.
    Rommer, P. S.
    Benecke, R.
    Zettl, U. K.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 385 - 396
  • [4] Paraneoplastic neurological syndromes
    Leypoldt, F.
    Wandinger, K. -P.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 336 - 348
  • [5] Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies
    Melzer, N.
    Meuth, S. G.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 359 - 372
  • [6] Monoclonal antibodies in treatment of multiple sclerosis
    Rommer, P. S.
    Dudesek, A.
    Stueve, O.
    Zettl, U. K.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 373 - 384
  • [7] Requirement for safety monitoring for approved multiple sclerosis therapies: an overview
    Rommer, P. S.
    Zettl, U. K.
    Kieseier, B.
    Hartung, H. -P.
    Menge, T.
    Frohman, E.
    Greenberg, B. M.
    Hemmer, B.
    Stueve, O.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 397 - 407
  • [8] Myasthenia gravis: an update for the clinician
    Sieb, J. P.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 408 - 418
  • [9] Multiple sclerosis treatment and infectious issues: update 2013
    Winkelmann, A.
    Loebermann, M.
    Reisinger, E. C.
    Zettl, U. K.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 425 - 438